StockData
CG Oncology, Inc. logo

CG Oncology, Inc. (CGON) stock

CGONNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 6, 2026Score 5/30
$78.94−5.84 (-6.89%)

Close on Nov 17, 2026Market cap $7.00BP/E –Yield –

CG Oncology r&d expenses

Research and development expenses are spending on new products and technology.

CG Oncology's R&D Expenses for the twelve months ending Sep 30, 2026 was $167.57M, up 47.7% year over year. For fiscal 2025 it was $116.64M, up 42.1% from the year before.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$116.64M+42.1%
FY2024Dec 31, 2024$82.10M+79.5%
FY2023Dec 31, 2023$45.75M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$39.22M+40.7%
Q2 FY2026Jun 30, 2026$54.66M+74.5%
Q1 FY2026Mar 31, 2026$43.73M+59.2%
Q4 FY2025Dec 31, 2025$29.96M+11.8%
Q3 FY2025Sep 30, 2025$27.88M+42.1%
Q2 FY2025Jun 30, 2025$31.33M+69.6%
Q1 FY2025Mar 31, 2025$27.47M+59.6%
Q4 FY2024Dec 31, 2024$26.80M+64.0%
Q3 FY2024Sep 30, 2024$19.62M+67.2%
Q2 FY2024Jun 30, 2024$18.47M+87.9%
Q1 FY2024Mar 31, 2024$17.21M+119.5%
Q4 FY2023Dec 31, 2023$16.34M–
Q3 FY2023Sep 30, 2023$11.74M–
Q2 FY2023Jun 30, 2023$9.83M–
Q1 FY2023Mar 31, 2023$7.84M–

More CG Oncology figures

See a number that looks wrong?